A Mesoporous Silica-Based Nano-Drug Co-Delivery System with Gemcitabine for Targeted Therapy of Pancreatic Cancer.
[OBJECTIVE] To investigate the efficacy and safety of the mesoporous silica-based nano-drug co-delivery system with gemcitabine (GEM) in the treatment of pancreatic cancer.
APA
Lin Q, Guan S, et al. (2024). A Mesoporous Silica-Based Nano-Drug Co-Delivery System with Gemcitabine for Targeted Therapy of Pancreatic Cancer.. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 34(12), 1456-1463. https://doi.org/10.29271/jcpsp.2024.12.1456
MLA
Lin Q, et al.. "A Mesoporous Silica-Based Nano-Drug Co-Delivery System with Gemcitabine for Targeted Therapy of Pancreatic Cancer.." Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, vol. 34, no. 12, 2024, pp. 1456-1463.
PMID
39648379
Abstract
[OBJECTIVE] To investigate the efficacy and safety of the mesoporous silica-based nano-drug co-delivery system with gemcitabine (GEM) in the treatment of pancreatic cancer.
[STUDY DESIGN] Experimental study. Place and Duration of the Study: Wenzhou Central Hospital, Zhejiang Province, China, between July 2022 and November 2023.
[METHODOLOGY] Ce6@MSN-Fe3O4/GEM@DPM nanoparticles were prepared and structurally characterised, then their drug loading and entrapment efficiency were calculated, and in vitro drug release and cytotoxicity assays were performed. In addition to that, mesoporous silica nanorods were prepared and structurally characterised for cellular uptake, cytotoxicity, and reactive oxygen species detection.
[RESULTS] The mesoporous silica nanoparticles were spherical in shape and possessed a unique core-shell structure. The prepared nanoparticles had good entrapment efficiency and drug loading, and exibited pharmacotoxic and phototoxic effects on cells. The mesoporous silica nanorods were taken up by pancreatic cancer cells and exbitied cytotoxicity.
[CONCLUSION] Mesoporous silica-based nano-drug co-delivery system, which carries GEM, is an effective targeted drug delivery system to provide new research ideas for the treatment of pancreatic cancer.
[KEY WORDS] Pancreatic cancer, Gemcitabine, Magnetic nanocomposites, Photodynamic therapy, Targeted drug delivery.
[STUDY DESIGN] Experimental study. Place and Duration of the Study: Wenzhou Central Hospital, Zhejiang Province, China, between July 2022 and November 2023.
[METHODOLOGY] Ce6@MSN-Fe3O4/GEM@DPM nanoparticles were prepared and structurally characterised, then their drug loading and entrapment efficiency were calculated, and in vitro drug release and cytotoxicity assays were performed. In addition to that, mesoporous silica nanorods were prepared and structurally characterised for cellular uptake, cytotoxicity, and reactive oxygen species detection.
[RESULTS] The mesoporous silica nanoparticles were spherical in shape and possessed a unique core-shell structure. The prepared nanoparticles had good entrapment efficiency and drug loading, and exibited pharmacotoxic and phototoxic effects on cells. The mesoporous silica nanorods were taken up by pancreatic cancer cells and exbitied cytotoxicity.
[CONCLUSION] Mesoporous silica-based nano-drug co-delivery system, which carries GEM, is an effective targeted drug delivery system to provide new research ideas for the treatment of pancreatic cancer.
[KEY WORDS] Pancreatic cancer, Gemcitabine, Magnetic nanocomposites, Photodynamic therapy, Targeted drug delivery.
MeSH Terms
Gemcitabine; Deoxycytidine; Pancreatic Neoplasms; Humans; Silicon Dioxide; Drug Delivery Systems; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Liberation; Nanoparticles; Porosity; Drug Carriers
같은 제1저자의 인용 많은 논문 (5)
- Overcoming adaptive resistance to KRASG12D blockade in pancreatic cancer through vertical pathway inhibition.
- Naringenin roled octacalcium phosphate reinforced with polyvinyl alcohol composite for sarcoma affected bone repair.
- Microfluidic chip coupled with photoelectrochemical/fluorescence dual-modal sensing system for the efficient enrichment and detection of circulating tumor cells.
- Drug-induced hyponatremia associated with sodium-glucose cotransporter 2 inhibitors, immune checkpoint inhibitors, and targeted anticancer agents.
- EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation.